Deal Capsule: Transactions In Chemicals & Pharmaceuticals July 2016

Table 1-2 Pharmaceuticals July 2016

by KPMG
The number of completed deals remained high in both sectors in HY1 2016. While total deal value for pharmaceuticals decreased, chemicals witnessed a 40% increase in HY1 2016 versus HY1 2015. Pharmaceutical M&A was impacted by stock market volatility, while new US regulatory rules struck down the $160 billion Pfizer-Allergan merger. Oncology and dermatology were key areas of interest for big pharma, who were especially keen on acquiring biotech assets. […] Read more

Deal Capsule: Transactions In Chemicals & Pharmaceuticals April 2016

Deal Capsule: Transactions In Chemicals & Pharmaceuticals April 2016

by KPMG
While the number of completed pharma deals were slightly higher in Q1 2016 versus Q1 2015, deal value was far lower in the absence of any >$10 billion completions. Only one deal exceeded $5 billion in Q1 2016 (versus 8 in Q1 2015). Specialization continues to be a driving force in Q1 2016, especially in sectors such as OTC, rare diseases and oncology. Declines in transaction values were also witnessed in chemicals. Downstream specialty chemicals was the leading focus area, notably in applications, resins and agrochemicals. […] Read more

2016 Global Chemical Industry Mergers And Acquisitions Outlook: A Quest For Focus

2016 Global Chemical Industry Mergers And Acquisitions Outlook: A Quest For Focus

by Deloitte
In the Deloitte Touche Tohmatsu Limited (Deloitte Global) 2015 Global chemical industry mergers and acquisitions outlook, record levels of chemical mergers and acquisitions (M&A) activity in 2014 were observed, with a prediction that strong M&A momentum would continue in the industry into 2015. While the number of global chemical deals was relatively flat in 2015, the strong M&A momentum has continued with the number of global chemical deals in 2015 exceeding the previous six-year average by over 6 percent. […] Read more

Chemicals M&A: Emerging Technologies

Chemicals M&A: Emerging Technologies

by Accenture
Mergers and acquisitions in the global chemicals industry have tumbled from their highs of the 2007­-2009 period, jolted by the Great Recession and despite the steady, albeit gradual, recovery in chemicals markets since then, M&A has not returned to those past levels. The reasons for the M&A slowdown are likely due to the uncertainty of global economic health, greater diligence in managing financials (i.e. debt and cash), volatile exchange rates and prices and a digestion of the major acquisitions of the recent past. […] Read more

2014 Global Chemical Industry Mergers And Acquisitions Outlook

by Deloitte
In 2013, the year’s activity validated once again that the only constant driver in chemicals mergers and acquisitions (M&A) is change. The year began with strong levels of M&A activity, but change and a slowdown emerged in the second quarter with moderate volume levels and deal sizes. […] Read more

2014 Global Chemical Industry Mergers And Acquisitions Outlook

by Deloitte
In 2013, the year’s activity validated once again that the only constant driver in chemicals mergers and acquisitions (M&A) is change. The year began with strong levels of M&A activity, but change and a slowdown emerged in the second quarter with moderate volume levels and deal sizes. […] Read more

2014 Global Chemical Industry Mergers And Acquisitions Outlook

by Deloitte
In 2013, the year’s activity validated once again that the only constant driver in chemicals mergers and acquisitions (M&A) is change. The year began with strong levels of M&A activity, but change and a slowdown emerged in the second quarter with moderate volume levels and deal sizes. […] Read more

Are you sure you
want to log out?

Request a Brochure

Request a Brochure

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!

Book a Demo

Book a Demo

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!